SCHEMBL3605620

SCHEMBL3605620

O=S1(=O)Nc2ccccc2N1c1ccc(F)c(F)c1F

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 1/20 0.40
OPRL1 P41146 8/20 0.36
OPRM1 P35372 2/20 0.33
KDM4E B2RXH2 1/20 0.33
RECQL P46063 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3608728 0.90 OPRL1 (0.36) PDE7AOPRL1OPRM1KDM4ERECQL
SCHEMBL3604966 0.85 MEN1 (0.39) OPRL1KDM4ERECQL
SCHEMBL3603631 0.83 SLC6A2 (0.41) OPRL1
SCHEMBL3599855 0.82 TP53 (0.42) OPRL1KDM4E
SCHEMBL3598276 0.81 SLC6A2 (0.41) OPRL1
SCHEMBL3600016 0.79 KDM4E (0.35) OPRL1OPRM1KDM4ERECQL
SCHEMBL3610877 0.79 OPRL1 (0.40) PDE7AOPRL1OPRM1KDM4ERECQL
SCHEMBL4053612 0.78 HCAR1 (0.37) OPRL1OPRM1KDM4ERECQL
SCHEMBL3607587 0.78 SLC6A2 (0.41) OPRL1OPRM1KDM4ERECQL
SCHEMBL3603070 0.76 SLC6A2 (0.40) OPRL1OPRM1KDM4ERECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2010-02-04 US disclosed
US-7601722-B2 Aryl sulfamide derivatives and methods of their use WYETH (US) 2009-10-13 US disclosed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-10 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029641-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PDE7A 1066/4885OPRL1 53/4885OPRM1 87/4885
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PDE7A 1343/4885OPRL1 55/4885OPRM1 79/4885
US-20080167303-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 PDE7A 1066/4885OPRL1 53/4885OPRM1 87/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.